Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Yohimbine does not affect fat distribution in men.

L Sax1

  • 1Department of Family and Community Medicine, Lancaster General Hospital, PA 17603.

International Journal of Obesity
|September 1, 1991
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The institute of medicine's "dietary reference intake" for phosphorus: a critical perspective.

Journal of the American College of Nutrition·2001
Same author

Bacterial pharyngitis in children.

The Journal of family practice·1998
Same author

Characteristics of spatiotemporal integration in the priming and rewarding effects of medial forebrain bundle stimulation.

Behavioral neuroscience·1991
Same author

Pesticide poisoning surveillance through regional poison control centers.

American journal of public health·1991
Same author

Unsupervised waveform classification for multi-neuron recordings: a real-time, software-based system. I. Algorithms and implementation.

Journal of neuroscience methods·1988
Same author

The binding of Ca2+ to the cell membrane increased by volatile anesthetics (alcohols, acetone, ether) which induce sensitization of nerve or muscle.

Biochimica et biophysica acta·1971

High-dose yohimbine did not impact body weight, cholesterol, or fat distribution in men over a six-month study. This study found no significant effects of yohimbine supplementation compared to placebo.

Area of Science:

  • Pharmacology
  • Human Physiology
  • Metabolic Health

Background:

  • Yohimbine, an alpha-2 adrenergic antagonist, has been investigated for potential effects on body composition and metabolism.
  • Previous research on yohimbine's efficacy in altering body fat and metabolic markers has yielded mixed results.
  • Understanding the impact of high-dose yohimbine on key health indicators is crucial for clinical application.

Purpose of the Study:

  • To evaluate the efficacy of high-dose yohimbine supplementation in modifying body weight, body mass index, and body fat percentage.
  • To assess the effects of yohimbine on lipid profiles, including total cholesterol and HDL cholesterol.
  • To determine yohimbine's influence on fat distribution, measured by waist-to-hip ratio and CT scans.

Main Methods:

Related Experiment Videos

  • A randomized, double-blind, placebo-controlled trial involving 47 men aged 42 years on average.
  • Participants received either high-dose yohimbine (peak 43 mg/day) or a placebo for six months.
  • Key variables measured included body weight, BMI, total cholesterol, HDL, body fat, waist-to-hip ratio, and CT-measured fat distribution.

    • Main Results:

    • No statistically significant differences were observed in body weight, BMI, or body fat percentage between the yohimbine and placebo groups.
    • Yohimbine treatment showed no effect on total cholesterol or HDL cholesterol levels compared to placebo.
    • Fat distribution, assessed by waist-to-hip ratio and CT scans, remained unchanged in the yohimbine group relative to the control group.

    Conclusions:

    • High-dose yohimbine supplementation over six months did not lead to significant changes in body composition or metabolic markers in the studied male population.
    • The findings suggest that yohimbine, at the tested dosage and duration, is not effective for weight management or improving lipid profiles.
    • Further research may be warranted to explore different dosages, durations, or specific subpopulations, but current evidence indicates limited efficacy.